Angela Vitrano

Dr. Angela Vitrano


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2021 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
Khaled MusallamKhaled Musallam
Khaled Musallam
AVAngela Vitrano
Angela Vitrano
Antonella MeloniAntonella Meloni
Antonella Meloni
SPSebastiano Addario Pollina
Sebastiano Addario Pollina
VMVito Di Marco
Vito Di Marco
T(the International Working Group on Thalassemia (IWG‐THAL)
the International Working Group on Thalassemia (IWG‐THAL)

20 November 2020 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
AVAngela Vitrano
Angela Vitrano
Antonella MeloniAntonella Meloni
Antonella Meloni
WPWalter Addario Pollina
Walter Addario Pollina
MKMehran Karimi
Mehran Karimi
AEAmal El‐Beshlawy
Amal El‐Beshlawy
Aurelio MaggioAurelio Maggio
Aurelio Maggio

19 June 2018 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
PDF file
LGLuciano Graffeo
Luciano Graffeo
AVAngela Vitrano
Angela Vitrano
SSSalvatore Scondotto
Salvatore Scondotto
GDGabriella Dardanoni
Gabriella Dardanoni
WAWalter Sebastiano Pollina Addario
Walter Sebastiano Pollina Addario
Aurelio MaggioAurelio Maggio
Aurelio Maggio

31 July 2025 in British Journal of Haematology
Verified
Journal Article
Closed access
Khaled MusallamKhaled Musallam
Khaled Musallam
AVAngela Vitrano
Angela Vitrano
AIAlessandro Inzerillo
Alessandro Inzerillo
RMRosario Di maggio
Rosario Di maggio
RBRita Barone
Rita Barone
Aurelio MaggioAurelio Maggio
Aurelio Maggio

25 July 2019 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
AVAngela Vitrano
Angela Vitrano
GRGiovan Battista Ruffo
Giovan Battista Ruffo
APAlessia Pepe
Alessia Pepe
DDDomenico Giuseppe D’aScola
Domenico Giuseppe D’aScola
VCVincenzo Caruso
Vincenzo Caruso
AMAurelio Maggio
Aurelio Maggio
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.

1 February 2024 in Medicina
Verified
Journal Article
Open access
PDF file
FDFabiana D’Esposito
Fabiana D’Esposito
VRViviana Randazzo
Viviana Randazzo
MVMaria Igea Vega
Maria Igea Vega
GEGabriella Esposito
Gabriella Esposito
PMPaolo Maltese
Paolo Maltese
EDElena D’alcamo
Elena D’alcamo
Background and Objectives. Retinitis pigmentosa (RP) is the most common inherited rod–cone dystrophy (RCD), resulting in nyctalopia, progressive visual field, and visual acuity decay in the late stages. The autosomal dominant form (ADRP) accounts for about 20% of RPs. Among the over 30 genes found to date related to ADRP, RP1 pathogenic variants have been identified in 5–10% of cases. In a cohort of RCD patients from the Palermo province on the island of Sicily, we identified a prevalent nonsense variant in RP1, which was associated with ADRP. The objective of our study was to analyse the clinical and molecular data of this patient cohort and to evaluate the potential presence of a founder effect. Materials and Methods. From 2005 to January 2023, 84 probands originating from Western Sicily (Italy) with a diagnosis of RCD or RP and their relatives underwent deep phenotyping, which was performed in various Italian clinical institutions. Molecular characterisation of patients and familial segregation of pathogenic variants were carried out in different laboratories using Sanger and/or next-generation sequencing (NGS). Results. Among 84 probands with RCD/RP, we found 28 heterozygotes for the RP1 variant c.2219C>G, p.Ser740* ((NM_006269.2)*, which was therefore significantly prevalent in this patient cohort. After a careful interview process, we ascertained that some of these patients shared the same pedigree. Therefore, we were ultimately able to define 20 independent family groups with no traceable consanguinity. Lastly, analysis of clinical data showed, in our patients, that the p.Ser740* nonsense variant was often associated with a late-onset and relatively mild phenotype. Conclusions. The high prevalence of the p.Ser740* variant in ADRP patients from Western Sicily suggests the presence of a founder effect, which has useful implications for the molecular diagnosis of RCD in patients coming from this Italian region. This variant can be primarily searched for in RP-affected subjects displaying compatible modes of transmission and phenotypes, with an advantage in terms of the required costs and time for analysis. Moreover, given its high prevalence, the RP1 p.Ser740* variant could represent a potential candidate for the development of therapeutic strategies based on gene editing or translational read-through therapy for suppression of nonsense variants.